Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REINFORCE
NCT06709196Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in postprocedural infection (SSI) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Infection-related readmission rate at 90 days. Started Jan 2025; status: recruiting.
02
Conditions
postprocedural infection (SSI)
Beyond the preview
Go deeper on NCT06709196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709196.